drugset / Trial / NCT02938013
deLIVER: Direct Acting Antiviral Effects on the Liver
RandomizedParallel-groupOpen-labelTreatment
Summary
Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting antivirals (DAAs)
Timeline
- Start
- 2017-01
- Primary completion
- 2019-09-30
- Completion
- 2020-09-30
Publications
- Sachithanandham J, Leep-Lazar J, Quinn J, Bowden K, Balasubramaniam P, Ward K, Ribeiro RM, Sulkowski MS, Balagopal A. Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation. J Infect Dis. 2025 Jun 2;231(5):1299-1308. doi: 10.1093/infdis/jiae598.
- Sachithanandham J, Balagopal A, Leep-Lazar J, Quinn J, Bowden K, Ward K, Ribeiro RM, Sulkowski MS. Second-Phase Hepatitis C Plasma Viral Kinetics Directly Reflects Reduced Intrahepatic Burden of Hepatitis C Virus. J Infect Dis. 2023 Aug 11;228(3):311-320. doi: 10.1093/infdis/jiad025.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Voxilaprevir | Small molecule | — | — |
| Background | Sofosbuvir | Small molecule | — | — |
| Background | velpatasvir | Other / unclassified | — | — |